Accenture plc
NYSE:ACNInformation Technology Services
-$27.07 today
- Market cap
- $141.42B
- Beta
- 1.07
- P/E (TTM)
- 10.1
- EPS (TTM)
- $12.78
- Dividend yield
- 4.94%
Volume 4.70M
Average 6.32M
ACN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Accenture plcNYSE: ACN
Research & Development · Q4 FY2026 · quarter ended Aug 2026
Research & development remains negative
Q4 FY2026 research & development was $0, compared with $817.3M a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2026, down 1.2 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-08-31 | 0 | -100.0% |
| FY2025 | 2025-08-31 | 817.3M | — |
| FY2024 | 2024-08-31 | 0 | — |
| FY2023 | 2023-08-31 | 0 | — |
| FY2022 | 2022-08-31 | 0 | — |
Research & Development vs competitors
How ACN compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -100.0% is the 2nd highest of 3, against a peer median of -44.1%.
- Research & development amounts to 0.0% of revenue for ACN, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $9.05B USD | +11.8% | +8.2% | 13.0% | |
| LTM Aug 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | ₹0 INR | — | — | 0.0% | |
| LTM Sep 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding ACN) | — | -44.1% | +8.2% | 0.0% | |
Competitors are the stored peer set for ACN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Aug 2022 | FY2023 Aug 2023 | FY2024 Aug 2024 | FY2025 Aug 2025 | FY2026 Aug 2026 |
|---|---|---|---|---|---|
| Revenue | 61.59B | 64.11B | 64.9B | 69.67B | 74.18B |
| Cost of Revenue | 41.89B | 43.38B | 43.73B | 47.44B | 50.41B |
| Gross Profit | 19.7B | 20.73B | 21.16B | 22.24B | 23.78B |
| Gross Margin | 32.0% | 32.3% | 32.6% | 31.9% | 32.0% |
| Research & Development | 0 | 0 | 0 | 817.3M | 0 |
| Selling, General & Admin | 10.33B | 10.86B | 11.13B | 11.39B | 12.06B |
| Operating Expenses | 10.33B | 11.92B | 11.57B | 12.01B | 12.37B |
| Depreciation & Amortization | 1.03B | 1.06B | 1.08B | 1.71B | 2.36B |
| EBITDA | 10.27B | 10.25B | 10.84B | 12.2B | 14.03B |
| EBITDA Margin | 16.7% | 16.0% | 16.7% | 17.5% | 18.9% |
| Operating Income | 9.37B | 8.81B | 9.6B | 10.23B | 11.41B |
| Operating Margin | 15.2% | 13.7% | 14.8% | 14.7% | 15.4% |
| Interest Income | 45.13M | 280.41M | 272.26M | 336.32M | 363.21M |
| Interest Expense | 47.32M | 47.53M | 58.97M | 228.56M | 303.4M |
| Other Income / Expenses | (171.01M) | 329.44M | 103.48M | 44.73M | (33.75M) |
| Income Before Tax | 9.2B | 9.14B | 9.7B | 10.27B | 11.37B |
| Pre-Tax Margin | 14.9% | 14.3% | 14.9% | 14.7% | 15.3% |
| Income Tax Expense | 2.21B | 2.14B | 2.28B | 2.44B | 2.85B |
| Net Income | 6.88B | 6.87B | 7.26B | 7.68B | 8.37B |
| Net Margin | 11.2% | 10.7% | 11.2% | 11.0% | 11.3% |
| EPS (Basic) | 10.87 | 10.90 | 11.57 | 12.29 | 13.66 |
| EPS (Diluted) | 10.71 | 10.77 | 11.44 | 12.15 | 13.56 |
| Weighted Avg Shares | 632.76M | 630.61M | 627.85M | 624.89M | 612.48M |
| Weighted Avg Shares (Diluted) | 642.84M | 638.59M | 635.94M | 632.44M | 617.5M |
Accenture plc
NYSE:ACN
Intrinsic Alpha fair value
Locked
Current Price
$239.28
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.